Holen Sie sich die Stockscreener-App
11.49
3.36%
-0.40
Schlusskurs vom Vortag:
$11.89
Offen:
$11.93
24-Stunden-Volumen:
21,648
Relative Volume:
0.49
Marktkapitalisierung:
$36.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-45.52M
KGV:
-1.1813
EPS:
-9.7265
Netto-Cashflow:
$-31.51M
1W Leistung:
+2.68%
1M Leistung:
+50.39%
6M Leistung:
+43.27%
1J Leistung:
+3,392%
1-Tages-Spanne:
$10.91
$11.93
1-Wochen-Bereich:
$9.50
$11.98
52-Wochen-Spanne:
$0.257
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Firmenname
Passage Bio Inc
Sektor
Branche
Telefon
(267) 866-0312
Adresse
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
11.49 | 38.14M | 0 | -45.52M | -31.51M | -9.7265 |
VRTX
Vertex Pharmaceuticals Inc
|
441.94 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.26 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
831.54 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.73 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.32 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Eingeleitet | Oppenheimer | Outperform |
| 2026-02-10 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-11-29 | Fortgesetzt | Wedbush | Outperform |
| 2024-09-03 | Eingeleitet | Rodman & Renshaw | Buy |
| 2022-03-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Herabstufung | Goldman | Buy → Neutral |
| 2021-07-01 | Eingeleitet | Raymond James | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-03-04 | Hochstufung | Goldman | Neutral → Buy |
| 2021-02-04 | Eingeleitet | Guggenheim | Buy |
| 2021-01-25 | Eingeleitet | Wedbush | Outperform |
| 2021-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-08-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-03-24 | Eingeleitet | Cowen | Outperform |
| 2020-03-24 | Eingeleitet | Goldman | Buy |
| 2020-03-24 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Passage Bio Inc Aktie (PASG) Neueste Nachrichten
Short Squeeze: What is the earnings history of Passage Bio IncTrade Entry Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Adeno-Associated Viral Vectors Market - openPR.com
PASG PE Ratio & Valuation, Is PASG Overvalued - Intellectia AI
Passage Bio (PASG) 2026 proxy details director elections, KPMG ratification and executive pay - Stock Titan
Passage Bio advances frontotemporal dementia trial and reports 2025 results - MSN
Stock List: Research Stocks from Around the World - GuruFocus
BOLD PE Ratio & Valuation, Is BOLD Overvalued - Intellectia AI
XCUR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Who’s Ahead in the Adeno-Associated Virus (AAV) Vectors in Gene Therapy Market? Competitive Insights for 2026 - EIN News
Passage Bio Inc Stock: Gene Therapy Pioneer Faces Clinical and Funding Hurdles in Biotech Arena - AD HOC NEWS
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Bond Watch: Can Passage Bio Inc reach all time highs this year2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Oppenheimer Initiates Coverage on PASG with Outperform Rating | - GuruFocus
Oppenheimer Initiates Passage Bio at Outperform - Moomoo
Baird initiates Passage Bio stock coverage with outperform rating By Investing.com - Investing.com India
Baird initiates Passage Bio stock coverage with outperform rating - Investing.com
Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - AD HOC NEWS
Oppenheimer initiates Passage Bio stock with outperform rating - Investing.com UK
Oppenheimer initiates Passage Bio stock with outperform rating By Investing.com - za.investing.com
Passage Bio, Inc. (NASDAQ:PASG) Receives $28.00 Average Price Target from Brokerages - Defense World
Passage Bio Inc Stock: Gene Therapy Innovator Focused on Rare Neurological Disorders Amid Biotech Vo - AD HOC NEWS
Passage Bio (PASG) price target increased by 21.85% to 40.39 - MSN
Options Flow: Can Sprout Social Inc sustain earnings growth2026 Institutional & Community Verified Watchlist Alerts - baoquankhu1.vn
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors - The Manila Times
MRKR PE Ratio & Valuation, Is MRKR Overvalued - Intellectia AI
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Passage BIO (PASG) CFO receives stock option grant for 15,610 shares - Stock Titan
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
PASG Surges 13% on Thin Volume — But No Catalyst to Back It - Bitget
Buybacks Report: Can Passage Bio Inc stock outperform in a bear market2026 Setups & Reliable Breakout Forecasts - baoquankhu1.vn
Passage Bio Inc Stock (ISIN: US70267E1055) Faces Biotech Headwinds Amid Analyst Optimism and Funding - AD HOC NEWS
Can Passage Bio Inc stock outperform in a bear market2026 Buyback Activity & Daily Entry Point Alerts - baoquankhu1.vn
Passage Bio Ends Hopewell Lab Lease, Extends Cash Runway - The Globe and Mail
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
Passage Bio Advances Frontotemporal Dementia Trial and Reports 2025 Results - MyChesCo
Weekly Trades: Is DISTW stock a hidden gemMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Passage Bio (NASDAQ:PASG) Lowered to Sell Rating by Wall Street Zen - Defense World
Will SBLK stock keep outperforming rivalsPortfolio Value Summary & AI Driven Price Forecasts - Naître et grandir
Portfolio Shifts: Does PRLD have declining or rising EPSTrade Signal Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Trade Report: What insider trading reveals about Passage Bio Inc. stockPortfolio Profit Report & Precise Entry and Exit Recommendations - Naître et grandir
Passage Bio (PASG) Gets a Buy from Chardan Capital - The Globe and Mail
PASG: Gene therapy for FTD-GRN advances with early-stage focus, strong biomarker data, and regulatory planning - TradingView
PASG: Gene therapy for FTD-GRN advances with safer dosing, strong biomarker data, and regulatory engagement - TradingView
Passage Bio (PASG) Analyst Rating: Canaccord Genuity Lowers Pric - GuruFocus
Passage Bio FY Income from Operations USD -49.296 Million - marketscreener.com
PASG Reports Drop in Cash Reserves for 2025 - GuruFocus
Passage Bio Reports 2025 Results, Advances FTD Program - TipRanks
Passage Bio is actively advancing its differentiated preclinical research project for Huntington's disease. - Bitget
Finanzdaten der Passage Bio Inc-Aktie (PASG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.94%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):